Asthma Attack/Asthma exacerabtion asthma attack
Conditions
Interventions
None listed
Sponsors
Franciscus
Eligibility
Age
16 Years to 99 Years
Inclusion criteria
Inclusion criteria: Adult (16+) patient diagnosed with asthma according to the GINA guidelines. Moderate to severe asthma, treated according to GINA guidelines with medium or high dose inhaled corticosteroids (with or without LABA) or treated with a low dose inhaled corticosteroids combined LABA or leukotriene-receptor antagonist. Asthma exacerbation, indication for systemic corticosteroids. Written personal informed consent, prior to any study procedures. Eligibility and willingness to present during an asthma exacerbation at the outpatient clinic facility of the study sites.
Exclusion criteria
Exclusion criteria: Immunosuppressive maintenance medication (azithromycin, systemic corticosteroids maintenance therapy and other) or recently (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameters are (1) the chosen treatment strategy (e.g. cumulative dose of prednisone and/or antibiotics), and (2) treatment effect measured on day 14. Treatment effect is determined on the need of additional AE treatments between day 0 and 14. Treatment effect is also measured by the physician and patient rated global evaluation of treatment effectiveness (GETE) score, difference in Asthma Control Questionnaire 5 (ACQ-5), difference in forced expiratory volume (FEV1) measured with handheld spirometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secundary study parameters are (1) to measure effect treatment on FeNO, eosinophils an neutrophils (at day 0 and day 14), (2) to monitor the side effects of prednisone, (3) to measure asthma control and stress and emotional wellbeing (questionnaire) and its possible correlation with the (patient experienced) treatment effect, and (4) to observe the chance on AAE relapse within 6 weeks. | — |
Countries
Netherlands
Contacts
Public ContactS Deelen
Franciscus
Outcome results
None listed